Cutaneous lupus erythematosus. Part 2: Diagnostics and therapy;Kutaner lupus erythematodes. Teil 2: Diagnostik und therapie

Hautarzt

Volumn 57, Issue 4, 2006, Pages 345-360

  Kuhn, A ^a,c   Gensch, K ^a   Stander S ^b   Bonsmann, G ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Antimalarial agents; Histology; Lupus erythematosus; Photoprovocation test; Therapy

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CEFUROXIME; CHLOROQUINE; CLOBETASOL; CLOFAZIMINE; CYCLOPHOSPHAMIDE; CYPROTERONE ACETATE; DANAZOL; DAPSONE; ETRETIN; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INFLIXIMAB; ISOTRETINOIN; LEFLUNOMIDE; MEPACRINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENYTOIN; PIMECROLIMUS; PRASTERONE SULFATE; RETINOID; SALAZOSULFAPYRIDINE; THALIDOMIDE; TSUKUBAENOLIDE; UNINDEXED DRUG;

AGRANULOCYTOSIS; ALLERGIC VASCULITIS; AMENORRHEA; APLASTIC ANEMIA; CONSTIPATION; DIAGNOSTIC PROCEDURE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; EYE TOXICITY; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; LABORATORY DIAGNOSIS; LIBIDO DISORDER; LIVER CIRRHOSIS; LIVER FIBROSIS; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PNEUMONIA; POLYNEUROPATHY; PROVOCATION TEST; PRURITUS; RETINA DISEASE; REVIEW; SCORING SYSTEM; SKIN BIOPSY; SKIN DEFECT; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; URTICARIA;

ANTIMALARIALS; AUTOANTIBODIES; BIOPSY; DIAGNOSIS, DIFFERENTIAL; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MICROSCOPY, FLUORESCENCE; SKIN; ULTRAVIOLET RAYS;

EID: 33645450711     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-006-1138-3     Document Type: Review

References (78)

1. Ackermann AB (1997) Lupus erythematosus. In: Ackermann AB (ed) Histologic diagnosis of inflammatory skin diseases. Williams & Wilkins, Baltimore, pp 525-546
2. ACR Ad Hoc Subcommittee on Response Criteria for Cutaneous Manifestations in SLE (2006) ACR Response criteria for cutaneous lupus erythematosus in clinical trials. (submitted)
3. Albrecht J, Berlin JA, Braverman IM et al. (2004) Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. Lupus 13:839-849
4. Albrecht J, Taylor L, Berlin JA et al. (2005) The CLA-SI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 125:889-894
5. Aringer M, Graninger WB, Steiner G, Smolen JS (2004) Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50:3161-3169
6. Bacman D, Kuhn A, Ruzicka T (2004) Dapsone and retinoids. In: Kuhn A, Lehmann P, Ruzicka T (eds) Cutaneous lupus erythematosus. Springer, Berlin Heidelberg New York Tokyo, pp 373-390
7. Bacman D, Tanbajewa A, Megahed M et al. (2003) Topical treatment with tacrolimus in lupus erythematosus tumidus. Hautarzt 54:977-979
8. Bleumink GS, ter Borg EJ, Ramselaar CG, Stricker BH (2001) Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 40:1317-1319
9. Bohm M, Gaubitz M, Luger TA et al. (2003) Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases. Dermatology 207:381-385
10. Calabrese L, Fleischer AB (2000)Thalidomide: current and potential clinical applications. Am J Med 108:487-495
11. Callen JP (2005) Management of "refractory" skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol 19:767-784
12. Callen JP, Spencer LV, Burruss JB, Holtman J (1991) Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 127: 515-522
13. Cardinali C, Caproni M, Fabbri P (1999) The composition of the lupus band test (LBT) on the sun-protected non-lesional (SPNL) skin in patients with cutaneous lupus erythematosus (CLE). Lupus 8:755-760
14. Casado E, Gratacos J, Tolosa C et al. (2006) Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis 65:385-390
15. Chambers CA (2003) Topical tacrolimus for cutaneous lupus erythematosus. Br J Dermatol 148:829
16. Charles PJ, Smeenk RJ, De Jong J et al. (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43:2383-2390
17. Clemmensen OJ, Olsen PZ, Andersen KE (1984) Thalidomide neurotoxicity. Arch Dermatol 120:338-341
18. Coburn PR, Shuster S (1982) Dapsone and discoid lupus erythematosus. Br J Dermatol 106:105-106
19. Coleman MD (1993) Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 129:507-513
20. Costedoat-Chalumeau N, Amoura Z, Huong du LT et al. (2005) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev 4:111-115
21. Costner MI, Sontheimer RD, Provost TT (2003) Lupus erythematosus. In: Sontheimer RD, Provost TT (eds) Cutaneous manifestations of rheumatic diseases. Williams & Wilkins, Philadelphia, pp 15-64
22. Crowson AN, Magro C (2001) The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol 28:1-23
23. Cuadrado MJ, Karim Y, Sanna G et al. (2005) Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med 118:246-250
24. David-Bajar KM, Davis BM (1997) Pathology, immunopathology, and immunohistochemistry in cutaneous lupus erythematosus. Lupus 6:145-157
25. Drake LA, Dinehart SM, Farmer ER et al. (1996) Guidelines of care for cutaneous lupus erythematosus. American Academy of Dermatology. J Am Acad Dermatol 34:830-836
26. Druke A, Gambichler T, Altmeyer P et al. (2004) 0.1% Tacrolimus ointment in a patient with subacute cutaneous lupus erythematosus. J Dermatolog Treat 15:63-64
27. Duna GF, Cash JM (1995) Treatment of refractory cutaneous lupus erythematosus. Rheum Dis Clin North Am 21:99-115
28. Fautrel B, Foltz V, Frances C et al. (2002) Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. Arthritis Rheum 46:1408-1409
29. Furner BB (1990) Subacute cutaneous lupus erythematosus response to isotretinoin. Int J Dermatol 29:587-590
30. Genereau T, Chosidow O, Danel C et al. (1999) High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol 135:1124-1125
31. Griffiths B, Mosca M, Gordon C (2005) Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19:685-708
32. Hall RP, Lawley TJ, Smith HR, Katz SI (1982) Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med 97:165-170
33. Herzinger T, Plewig G, Rocken M (2004) Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum 50:3045-3046
34. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
35. 34a. Janssens AS, Lashley EE, Out-Luiting CJ, Willemze R, Pavel S, de Gruijl FR (2005) UVB-induced leucocyte trafficking in the epidermis of photosensitive lupus erythematosus patients: normal depletion of Langerhans cells. Exp Dermatol 14:138-142
36. Jewell ML, McCauliffe DP (2000) Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 42:983-937
37. Kanekura T, Yoshii N, Terasaki K et al. (2003) Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 148:353-356
38. Karim Y, Cuadrado MJ (2004) Thalidomide in cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T (eds) Cutaneous lupus erythematosus. Springer, Berlin Heidelberg New York Tokyo, pp 391-402
39. Knop J, Bonsmann G, Happle R et al. (1983) Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 108:461-466
40. Kourbeti IS, Boumpas DT (2005) Biological therapies of autoimmune diseases. Curr Drug Targets Inflamm Allergy 4:41-46
41. Kreuter A, Gambichler T, Breuckmann F et al. (2004) Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 51:407-410
42. Kuhn A, Becker-Wegerich PM, Ruzicka T, Lehmann P (2000) Successful treatment of discoid lupus erythematosus with argon laser. Dermatology 201:175-177
43. Kuhn A, Hefter H, Ruzicka T, Lehmann P (2001) Wiederentdeckung von Thalidomid. Hautarzt 52:726-733
44. Kuhn A, Sonntag M, Richter-Hintz D et al. (2001) Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol 45:86-95
45. Lehmann P (2004) Topical treatment of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T (eds) Cutaneous lupus erythematosus. Springer, Berlin Heidelberg New York Tokyo, pp 337-346
46. Lehmann P, Hölzle E, Kind P et al. (1990) Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol 22:181-187
47. Lindskov R, Reymann F (1986) Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 172:214-217
48. Louis E, Vermeire S, Rutgeerts P et al. (2002) A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 37:818-824
49. Maurice PD, Maddox AJ, Green CA et al. (2005) Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol 152:451-458
50. McCauliffe DP (2001) Cutaneous lupus erythematosus. Semin Cutan Med Surg 20:14-26
51. Meurer M (2003) Childhood discoid lupus erythematosus and antimalarials. Dermatology 207:133
52. Millard TP, Lewis CM, Khamashta MA et al. (2001) Familial clustering of polymorphic light eruption in relatives of patients with lupus erythematosus: evidence of a shared pathogenesis. Br J Dermatol 144:334-338
53. Neale R, Williams G, Green A (2002) Application patterns among participants randomized to daily sunscreen use in a skin cancer prevention trial. Arch Dermatol 138:1319-1325
54. Ochonisky S, Verroust J, Bastuji-Garin S et al. (1994) Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 130:66-69
55. Ochsendorf FR (2004) Antimalarials. In: Kuhn A, Lehmann P, Ruzicka T (eds) Cutaneous lupus erythematosus. Springer, Berlin Heidelberg New York Tokyo, pp 347-372
56. Parodi A, Rebora A (1997) ARA and EADV criteria for classification of systemic lupus erythematosus in patients with cutaneous lupus erythematosus. Dermatology 194:217-220
57. Pelle MT, Callen JP (2002) Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 138:1231-1233
58. Petri M, Kim MY, Kalunian KC et al. (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353:2550-2558
59. Pisoni CN, Obermoser G, Cuadrado MJ et al. (2005) Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 23:393-396
60. Ruzicka T, Goerz G (1981) Dapsone in the treatment of lupus erythematosus. Br J Dermatol 104:53-56
61. Ruzicka T, Goerz G (1981) Systemic lupus erythematosus and vasculitic urticaria. Effect of dapsone and complement levels. Dermatologica 162:203-205
62. Ruzicka T, Meurer M, Bieber T (1988) Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol 124:897-902
63. Ruzicka T, Meurer M, Braun-Falco O (1985) Treatment of cutaneous lupus erythematosus with etretinate. Acta Derm Venereol 65:324-329
64. Saito S, Ikezawa Z, Miyamoto H, Kim S (1994) A case of the "dapsone syndrome". Clin Exp Dermatol 19:152-156
65. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L et al. (2005) A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 353:2539-2549
66. Schneider M, Fischer-Betz R, Gensch K et al. (2006) New trends in topical and systemic immunosuppressive treatment. In: Sarzi-Putini P, Doria A, Giampetro G, Kuhn A (eds) The skin in systemic autoimmune disease. Elsevier, Amsterdam, pp 325-336
67. Schneider SW, Luger TA (2004) Experimental therapies in cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T (eds) Cutaneous lupus erythematosus. Springer, Berlin Heidelberg New York Tokyo, S 419-436
68. Schulz EJ, Menter MA (1971) Treatment of discoid and subacute lupus erythematosus with cyclophosphamide. Br J Dermatol 60-65
69. Shornick JK, Formica N, Parke AL (1991) Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol 24:49-52
70. Sticherling M (2004) Immunosuppressive drugs in cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T (eds) Cutaneous lupus erythematosus. Springer, Berlin Heidelberg New York Tokyo, pp 403-418
71. Tseng S, Pak G, Washenik K et al. (1996) Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 35:969-979
72. Ueki H (2005) Koebner phenomenon in lupus erythematosus with special consideration of clinical findings. Autoimmun Rev 4:219-223
73. Von Schmiedeberg S, Rönnau AC, Schuppe HC et al. (2000) Kombination der Antimalariamittel Mepacrin und Chloroquin bei therapieresistentem Lupus erythematodes. Hautarzt 51:82-85
74. Walker SL, Kirby B, Chalmers RJ (2002) The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol 147:405-406
75. Wenzel J, Bieber T, Uerlich M, Tuting T (2003) Systemic treatment of cutaneous lupus erythematosus. J Dtsch Dermatol Ges 1:694-704
76. Wenzel J, Brahler S, Bauer R et al. (2005) Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 153:157-162
77. Wozniacka A, McCauliffe DP (2005) Optimal use of antimalarials in treating cutaneous lupus erythematosus. Am J Clin Dermatol 6:1-11
78. Yoshimasu T, Ohtani T, Sakamoto T et al. (2002) Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 12:50-52